These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19915844)

  • 1. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
    Thompson KL; Rosenzweig BA; Zhang J; Knapton AD; Honchel R; Lipshultz SE; Retief J; Sistare FD; Herman EH
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):303-14. PubMed ID: 19915844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Herman EH; Zhang J; Chadwick DP; Ferrans VJ
    Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
    Vijay V; Moland CL; Han T; Fuscoe JC; Lee T; Herman EH; Jenkins GR; Lewis SM; Cummings CA; Gao Y; Cao Z; Yu LR; Desai VG
    Toxicol Appl Pharmacol; 2016 Mar; 295():68-84. PubMed ID: 26873546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
    Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
    Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
    Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
    Héon S; Bernier M; Servant N; Dostanic S; Wang C; Kirby GM; Alpert L; Chalifour LE
    Am J Physiol Heart Circ Physiol; 2003 Aug; 285(2):H499-506. PubMed ID: 12714334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway.
    Tomlinson L; Lu ZQ; Bentley RA; Colley HE; Murdoch C; Webb SD; Cross MJ; Copple IM; Sharma P
    Biomed Pharmacother; 2019 Apr; 112():108637. PubMed ID: 30798127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
    Pandey S; Kuo WW; Shen CY; Yeh YL; Ho TJ; Chen RJ; Chang RL; Pai PY; Viswanadha VP; Huang CY; Huang CY
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C235-C243. PubMed ID: 31116582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
    Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
    Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulforaphane protects the heart from doxorubicin-induced toxicity.
    Singh P; Sharma R; McElhanon K; Allen CD; Megyesi JK; Beneš H; Singh SP
    Free Radic Biol Med; 2015 Sep; 86():90-101. PubMed ID: 26025579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.